Characterization and in vivo effect of cellular and protein vaccines
| Immunizing agent . | Xenogeneic cell vaccine, enhanced TAA presentation . | Possible interaction of vaccine cell and APC by FcR . | Presence of the Id . | FcR-targeting of the Id . | Long-term survivors after vaccination and wild-type A20 challenge, % . |
|---|---|---|---|---|---|
| BiV cells | + | + | + | + | 100 |
| A20 wild-type cells | − | − | + | − | 0 |
| BiV protein | − | − | + | + | 18 |
| BiVneg cells | + | − | + | − | 20 |
| BiV protein/BiVneg cells | + | − | + | + | 42 |
| BiV protein/26II6 cells | − | − | + | + | 0 |
| BiVIdneg cells | + | + | − | − | 70 |
| Immunizing agent . | Xenogeneic cell vaccine, enhanced TAA presentation . | Possible interaction of vaccine cell and APC by FcR . | Presence of the Id . | FcR-targeting of the Id . | Long-term survivors after vaccination and wild-type A20 challenge, % . |
|---|---|---|---|---|---|
| BiV cells | + | + | + | + | 100 |
| A20 wild-type cells | − | − | + | − | 0 |
| BiV protein | − | − | + | + | 18 |
| BiVneg cells | + | − | + | − | 20 |
| BiV protein/BiVneg cells | + | − | + | + | 42 |
| BiV protein/26II6 cells | − | − | + | + | 0 |
| BiVIdneg cells | + | + | − | − | 70 |
Results are summarized from 2 to 3 independent experiments. Examples of individual experiments are given in Figure 1.